Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance.
Currently, the primary treatment revolves around checkpoint inhibitors (CPIs) and tyrosine kinase inhibitors (TKIs). However, prognosis takes a downturn when patients progress on these drug classes, highlighting the pressing need for innovative solutions.
At AACR 2024, findings from a Phase 1 (COBALT-RCC) trial investigating allogeneic CAR T cell treatment (CTX130) in p...